Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers lifted its stake in Scholar Rock Holding Co. (NASDAQ:SRRK) by 7.7% during the second quarter, HoldingsChannel reports. The institutional investor owned 101,278 shares of the company’s stock after acquiring an additional 7,222 shares during the period. Rhumbline Advisers’ holdings in Scholar Rock were worth $844,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of SRRK. Charles Schwab Investment Management Inc. grew its position in shares of Scholar Rock by 30.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 394,138 shares of the company’s stock valued at $7,410,000 after buying an additional 91,754 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Scholar Rock by 616.8% in the 4th quarter. BNP Paribas Financial Markets now owns 48,372 shares of the company’s stock valued at $909,000 after buying an additional 41,624 shares during the last quarter. Trexquant Investment LP purchased a new position in shares of Scholar Rock in the 4th quarter valued at $1,359,000. TD Asset Management Inc grew its position in shares of Scholar Rock by 1.1% in the 4th quarter. TD Asset Management Inc now owns 339,894 shares of the company’s stock valued at $6,390,000 after buying an additional 3,600 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Scholar Rock in the 4th quarter valued at $711,000. 91.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on SRRK shares. BMO Capital Markets increased their target price on shares of Scholar Rock from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Wedbush reissued an “outperform” rating and set a $23.00 price objective on shares of Scholar Rock in a research report on Thursday, August 8th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Scholar Rock in a research report on Tuesday, June 25th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $26.43.

Scholar Rock Stock Down 7.7 %

SRRK stock opened at $8.67 on Tuesday. Scholar Rock Holding Co. has a one year low of $6.18 and a one year high of $21.17. The stock has a market capitalization of $691.47 million, a PE ratio of -4.15 and a beta of 0.82. The company has a debt-to-equity ratio of 0.36, a quick ratio of 6.04 and a current ratio of 6.04. The company has a fifty day moving average of $8.92 and a 200-day moving average of $11.14.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Thursday, August 8th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.01. During the same quarter last year, the firm posted ($0.47) earnings per share. As a group, analysts expect that Scholar Rock Holding Co. will post -2.39 EPS for the current year.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.